

Shiraz University Association

Presents

New Frontiers in Understanding and the Management of Type 2 Diabetes

Saturday, November 3, 2007

Manhattan Beach Marriott Hotel

1400 Parkview Avenue

Manhattan Beach, CA, 90266

(310) 546-7511

Khosrow Nasr, MD - Program Chair

Faramarz Ismail Beigi, MD, PhD - Program Co-Chair

Etie Moghissi, MD, FACP, FACE - Program Co-Chair

7:00 a.m. – 8:00 a.m. **Continental Breakfast**
Exhibit Hall Open

7:50 a.m. – 8:05 a.m. **Welcome & Opening Remarks**
Khosrow Nasr, MD – Program Chair
Etie S. Moghissi, MD, FACP, FACE – Program Co-Chair

8:05 a.m. – 10:00 a.m. SESSION I

8:05 a.m. – 8:45 a.m. **ZABIH GHORBAN LECTURE**
New understanding in the Pathophysiology of Type 2 Diabetes and the role of Oral Antidiabetic Therapy
Faramarz Ismail Beigi, MD, PhD
Objectives:

1. Review the pathogenesis of type 2 diabetes
2. Discuss the role of Amylin and glucagon in hyperglycemic states
3. Outline the major classes of antidiabetic agents and discuss their mode of action

8:45 a.m. – 9:15 a.m. *Incretin-based Therapies in Type 2 Diabetes: in the Clinic, in the Pipeline*
Hugh S. Nasr, MD, FACE
Objectives:

1. Review the modes of action and clinical potential of incretin-based therapies in Type 2 Diabetes.
2. Outline the clinical considerations in the selection of pharmacotherapy for Type 2 Diabetes.
3. Discuss patient selection, treatment initiation, clinical effects, of exenatide and DPP4 inhibitors in clinical practice.

9:15 a.m. – 9:45 a.m. *Insulin Therapy in Type 2 Diabetes: Indications, Initiation, and Innovations*
Etie S. Moghissi, MD, FACP, FACE
Objectives:

1. Outline the pathophysiology of progressive beta cell dysfunction in Type 2 Diabetes.
2. Utilize an understanding of the action patterns of insulin type in the design of treatment programs for Type 2 Diabetes that restore normal glucose patterns in the pre and postprandial periods.
3. Recognize evolving and innovative directions for insulin replacement therapy

9:45 a.m. – 10:00 a.m. **Questions & Answers**

10:00 a.m.– 10:30 a.m. **Break**
Exhibit Hall Open

10:30 a.m.– 1:00 p.m. SESSION II

10:30 a.m.– 10:45 a.m. *Nonalcoholic Steatohepatitis: , Pathogenesis and Treatment*
Khosrow Nasr, MD

Objectives:

1. Identify the presence of fatty liver and how to differentiate from other etiologies of liver disease.
2. Discuss the diagnosis of steatohepatitis and the degree of damage and prognosis.
3. Utilize available information to follow and manage patients with fatty liver and steatohepatitis.

10:45 a.m. – 11:00 a.m. *Diabetic Gastroparesis: Pathogenesis and Treatment*
Saeed Bagheri, MD

Objectives:

1. Discuss pathogenesis of diabetic gastroparesis.
2. Discuss strategies for detection of diabetic gastroparesis.
3. Outline the management of gastroparesis.

11:00 a.m. – 11:15 a.m. **Questions & Answers**

11:15 a.m. – 11:45 a.m. *Diabetic Nephropathy : Diagnosis, Prevention, and Treatment*
Asghar Rastegar, MD

Objectives:

1. Discuss epidemiology and natural history of diabetic nephropathy.
2. Discuss pathogenesis of diabetic nephropathy.
3. Discuss strategies for detection of diabetic nephropathy and prevention of renal failure.

11:45 a.m. – 12:15 p.m. **Panel Discussion**
Jamshid Honari, MD
Bahar Bastani, MD
Manoocher Soleimani, MD

12:15 p.m. – 12:45 p.m. *Diabetic Neuropathy: New Concepts in Evaluation and Treatment*
Mohammad Rostami, MD

Objectives:

1. Describe the physiology and prevention of diabetic peripheral neuropathy.
2. Discuss the new approached in treatment of diabetic peripheral neuropathy.

12:45 p.m. – 1:00 p.m. **Questions & Answers**

1:00 p.m. – 1:30 p.m. **Lunch**

1:30 p.m. – 2:30 p.m. **Key Note Speakers**

Integrated Neurohormonal Therapy for Obesity: Harnessing Additive/Synergistic Effects of Adipocyte-, Islet-, and Gut-Derived Hormones

Hubert C. Chen, MD

Objectives:

1. Role of neurohormones in the regulation of food intake and energy expenditure.
2. Clinical results with pramlintide, an amylin agonist.
3. Potentials of an integrated hormonal approach: Effects of combining amylin, PYY, and leptin on food intake and body weight in animal models.
4. Implications for future medical therapy for obesity.

Endocrine and Metabolic Effects of HIV and its Treatment

Mohsen Shahmanesh, MD, FRCP

Objectives:

1. To provide an overview of the metabolic complications of HIV and its treatments.
2. Discuss the association of lipodystrophy, diabetes, and dyslipidaemia and the increasing risks of cardiovascular risk and HIV infection.
3. Review the pathogenesis and treatment option in HIV infection.

2:30 p.m.

Adjournment

FACULTY:

Saeed A. Bagheri, MD

Assistant Clinical Professor of Medicine
Pennsylvania State University
Private Practice – Gastroenterology
Lebanon, PA

Bahar Bastani, MD

Professor of Medicine - Nephrology
Saint Louis University
Saint Louis, MO

Nasser Borougerdi, MD

Hubert C. Chen, MD

Director of Clinical Research
Amylin Pharmaceuticals, Inc.
San Diego, CA

Jamshid Honari, MD

Clinical Associate Professor of Medicine
University of Washington
Seattle Washington

Faramarz Ismail Beigi, MD, PhD

Professor of Medicine, Physiology and Biophysics, and Molecular Biology
Chief, Division of Clinical and Molecular Endocrinology
Case Western Reserve University
Cleveland, Ohio

Etie S. Moghissi, MD, FACP, FACE

Associate Clinical Professor of Medicine
University of California, Los Angeles
Medical Director, In Patient Diabetes Program & Diabetes Care Center

Centinela Hospital Medical Center
Inglewood, CA

Hugh S. Nasr, MD, FACE

Private Practice – Internal Medicine, Endocrinology, & Geriatrics
Palm Springs, CA

Khosrow Nasr, MD

Private Practice – Capitol Gastroenterology Medical Group
Roseville, CA

Asghar Rastegar, MD

Professor of Medicine
Associate Chairman for Academic Affairs
Yale University School of Medicine
New Haven, CT

A.M. Rostami, MD, PhD

Professor & Chair, Department of Neurology
Thomas Jefferson University
Philadelphia, PA

Mohsen Shahmanesh, MD, FRCP

Whittall Street Clinic
University Hospital Birmingham
Birmingham, UK

Manoocher Soleimani, MD

James F. Heady Professor of Medicine
Director, Division of Nephrology
and Hypertension
University of Cincinnati